| Industry | Drug Manufacturers—General |
| Sector | Health Care |
| Main Index | LSE |
| Company's (investor relations) website | Company Website |
| Next earnings report | NaT |
| Reporting currency | USD |
| Fiscal year period | 01/01-31/12 |
| Reporting cycle | Quarter |
| Last processed report | Q1-2022 |
| Market Capitalization (in million) | $ 15,689,100 |
| Enterprise value | $ 15,730,222 |
| Shares outstanding (in million) | 1,550.0 |
| ROE (Return on Equity) | 0.3% |
| ROA (Return on Assets) | 2.5% |
| EPS (Earnings Per Share) | $ 0.07 |
| PE (Price/Earnings) | 7,128.2 |
| Beta | 0.13 |
| Implicit value range | 440.12834723164724|
| Investment advice | Buy |
| Trading advice (based on moving averages) | Sell |
| Latest StockAdvisor Algorithmic advice see Return on Advice Graph | Sell |
| Fundamental Strength (scale 0 - 100) | 39 |
| Trading Strength (scale 0 - 100) | 41 |
| 1 year performance | -10.55% |
| 52 Weeks range | $ 101.8 - 12294 |
| 10 Day's Moving Average | Downtrend |
| 50 Day's Moving Average | Downtrend |
| 200 Day's Moving Average | Downtrend |
| Revenue (last year in million) | $ 37,417 |
| 5 year Revenue growth (5 year CAGR) | -14.61% |
| Net income (last year in million) | $ 112 |
| 5 year Net income growth (5 year CAGR) | -17.91% |
| 1 year target | $ 39,751.80 |
| 3 year target | $ 47,820.85 |
| AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. |
| Amgen Inc. |
| AstraZeneca PLC |
| Bayer AG |
| Biogen Inc. |
| Gilead Sciences Inc. |
| GlaxoSmithKline plc |
| Grifols S.A. |
| Johnson & Johnson Inc. |
| Description | 2020 | 2021 | 2022 | 2023 * | 2024 * | 2025 * |
| Revenue | $ 13,988 | $ 37,417 | $ 50,939 | $ 61,668 | $ 69,665 | $ 75,775 |
| Net income | $ 1,660 | $ 112 | $ 2,194 | $ 3,533 | $ 4,312 | $ 4,780 |
| EPS | $ 0.65 | $ 0.07 | $ 1.42 | $ 2.28 | $ 2.78 | $ 3.08 |
| PE | 11,217.59 | 120,097.32 | 28,606.54 | 15,673.68 | 14,290.62 | 14,232.08 |
| Prices eoy | $ 7,324.00 | $ 8,678.00 | $ 40,485.30 | $ 35,730.62 | $ 39,751.80 | $ 43,889.40 |
| Dividend | $ 0.00 | $ 0.00 | $ -1.01 | $ -2.11 | $ -2.61 | $ -3.66 |
| Div-% | 0.0% | 0.0% | 0.0% | -0.0% | -0.0% | -0.0% |
| Description | Q1-22 | Q2-22 * | Q3-22 * | Q4-22 * | Q1-23 * | Q2-23 * | Q3-23 * | Q4-23 * |
| Revenue | $ 11,390 | $ 12,352 | $ 13,059 | $ 14,138 | $ 14,663 | $ 15,192 | $ 15,601 | $ 16,212 |
| Net income | $ 386 | $ 545 | $ 648 | $ 615 | $ 556 | $ 1,494 | $ 528 | $ 956 |
| EPS | $ 0.25 | $ 0.35 | $ 0.42 | $ 0.40 | $ 0.36 | $ 0.96 | $ 0.34 | $ 0.62 |
| PE | -14,773.85 | -15,670.36 | 24,773.05 | 28,606.54 | 5,733.85 | 10,860.77 | 17,493.55 | 15,673.68 |
| Prices eoq | $ 10,132.00 | $ 10,800.00 | $ 9,944.00 | $ 40,485.30 | $ 8,742.12 | $ 23,208.76 | $ 36,034.66 | $ 35,730.62 |
| NORM | ||||
| Description | Actuals | Progressive | Neutral | Conservative |
| Solvency | 23.4% | < 25% | 25-35% | > 35% |
| ROE (return on equity) | 10.6% | > 12% | 10-12% | < 10% |
| ROA (return on assets) | 2.5% | > 5% | 5% | < 5% |
| Current ratio | 1.0 | < 1 | 1-1.5 | > 1.5 |
| Turnover rate | 4.8 | < 1 | 1-1.5 | > 1.5 |
| WACC | 3.28% | > 10% | 10% | < 10% |
| Beta | 0.13 | > 1 | 1 | < 1 |